{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T20:56:31Z","timestamp":1792356991390,"version":"4.4.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.ejim.2011.06.006","type":"journal-article","created":{"date-parts":[[2011,7,15]],"date-time":"2011-07-15T07:35:44Z","timestamp":1310715344000},"page":"554-560","source":"Crossref","is-referenced-by-count":206,"title":["Extra-articular manifestations of ankylosing spondylitis: Prevalence, characteristics and therapeutic implications"],"prefix":"10.1016","volume":"22","author":[{"given":"Abdellah","family":"El Maghraoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.ejim.2011.06.006_bb0005","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","article-title":"Ankylosing spondylitis: an overview","volume":"61","author":"Sieper","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0010","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0755-4982(04)98954-3","article-title":"Ankylosing spondylitis","volume":"33","author":"El Maghraoui","year":"2004","journal-title":"Presse Med"},{"key":"10.1016\/j.ejim.2011.06.006_bb0015","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/rheumatology\/kep146","article-title":"Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice","volume":"48","author":"Elewaut","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejim.2011.06.006_bb0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.berh.2006.03.008","article-title":"Uveitis","volume":"20","author":"Munoz-Fernandez","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0025","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/ard.2007.075754","article-title":"Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review","volume":"67","author":"Zeboulon","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0030","first-page":"1277","article-title":"Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period","volume":"30","author":"Munoz-Fernandez","year":"2003","journal-title":"J Rheumatol"},{"issue":"Pt 3A","key":"10.1016\/j.ejim.2011.06.006_bb0035","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/eye.2000.84","article-title":"Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis","volume":"14","author":"Benitez-Del-Castillo","year":"2000","journal-title":"Eye"},{"key":"10.1016\/j.ejim.2011.06.006_bb0040","first-page":"81","article-title":"Prevention of acute anterior uveitis associated with spondylarthropathy induced by salazosulfapyridine","volume":"60","author":"Dougados","year":"1993","journal-title":"Rev Rhum Ed Fr"},{"key":"10.1016\/j.ejim.2011.06.006_bb0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ncprheum0097","article-title":"Does anti-TNF therapy decrease the incidence of anterior uveitis in patients with ankylosing spondylitis?","volume":"2","author":"Levy-Clarke","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0050","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2011.06.006_bb0055","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0060","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0065","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0070","first-page":"2306","article-title":"The gut in ankylosing spondylitis and other spondyloarthropathies: inflammation beneath the surface","volume":"30","author":"De Keyser","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0075","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.berh.2006.03.010","article-title":"Ankylosing spondylitis and bowel disease","volume":"20","author":"Rudwaleit","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0080","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0085","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0090","first-page":"532","article-title":"New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept","volume":"35","author":"Song","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0095","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","article-title":"Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents","volume":"57","author":"Braun","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2011.06.006_bb0100","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ejim.2011.06.006_bb0105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0110","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jbspin.2005.10.006","article-title":"Psoriatic arthritis","volume":"72","author":"Goupille","year":"2005","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ejim.2011.06.006_bb0115","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jbspin.2009.03.003","article-title":"Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: Development of recommendations for clinical practice based on published evidence and expert opinion","volume":"76","author":"Lavie","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ejim.2011.06.006_bb0120","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.2165\/00003495-200767170-00009","article-title":"Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis","volume":"67","author":"Hoy","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2011.06.006_bb0125","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3899\/jrheum.081122","article-title":"Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire","volume":"36","author":"Barra","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/03009740802004966","article-title":"Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment","volume":"37","author":"Brodszky","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0135","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ncprheum0880","article-title":"Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis","volume":"4","author":"Gladman","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0140","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jbspin.2007.06.011","article-title":"Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy","volume":"75","author":"Wendling","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ejim.2011.06.006_bb0145","first-page":"1290","article-title":"Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes","volume":"32","author":"Karberg","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/BOR.0b013e328133f5b3","article-title":"Osteoporosis and vertebral fractures in ankylosing spondylitis","volume":"19","author":"Geusens","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0155","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jbspin.2003.06.002","article-title":"Osteoporosis and ankylosing spondylitis","volume":"71","author":"El Maghraoui","year":"2004","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ejim.2011.06.006_bb0160","first-page":"2205","article-title":"Osteoporosis, body composition, and bone turnover in ankylosing spondylitis","volume":"26","author":"El Maghraoui","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0165","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s10067-004-1039-8","article-title":"Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis","volume":"24","author":"El Maghraoui","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0170","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/qjmed\/hcn022","article-title":"DXA scanning in clinical practice","volume":"101","author":"El Maghraoui","year":"2008","journal-title":"QJM"},{"key":"10.1016\/j.ejim.2011.06.006_bb0175","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s001980170084","article-title":"Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study","volume":"12","author":"Maillefert","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ejim.2011.06.006_bb0180","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1002\/1529-0131(199911)42:11<2319::AID-ANR9>3.0.CO;2-G","article-title":"Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study","volume":"42","author":"Gratacos","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2011.06.006_bb0185","first-page":"1877","article-title":"Fracture risk in patients with ankylosing spondylitis: a population based study","volume":"21","author":"Cooper","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0190","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/bmj.300.6724.563","article-title":"Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis","volume":"300","author":"Ralston","year":"1990","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2011.06.006_bb0195","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bone.2008.12.028","article-title":"Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis","volume":"44","author":"Ghozlani","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.ejim.2011.06.006_bb0200","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/ard.2008.100503","article-title":"Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case control study","volume":"68","author":"Vosse","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0205","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2005.044081","article-title":"Determinants of hyperkyphosis in patients with ankylosing spondylitis","volume":"65","author":"Vosse","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0210","first-page":"1981","article-title":"Clinical vertebral fractures in patients with ankylosing spondylitis","volume":"31","author":"Vosse","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0215","first-page":"855","article-title":"Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment","volume":"35","author":"Briot","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0220","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1136\/hrt.2007.132787","article-title":"Valvular and coronary heart disease in systemic inflammatory diseases: systemic disorders in heart disease","volume":"94","author":"Roldan","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2011.06.006_bb0225","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10067-005-1117-6","article-title":"Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population?","volume":"25","author":"Brunner","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0230","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/ard.51.6.705","article-title":"The heart in ankylosing spondylitis","volume":"51","author":"O'Neill","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0235","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/ard.52.3.174","article-title":"Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis","volume":"52","author":"Lehtinen","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0240","first-page":"S11","article-title":"Ankylosing spondylitis\u2014cardiac manifestations","volume":"20","author":"Lautermann","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0245","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/ard.2009.110593","article-title":"Ankylosing spondylitis; a risk factor for myocardial infarction?","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0250","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/rheumatology\/kei145","article-title":"Impaired endothelial function in patients with ankylosing spondylitis","volume":"45","author":"Sari","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejim.2011.06.006_bb0255","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.atherosclerosis.2006.11.003","article-title":"Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis","volume":"196","author":"Caliskan","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0260","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.24492","article-title":"Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis","volume":"60","author":"van Eijk","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2011.06.006_bb0265","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.semarthrit.2004.07.010","article-title":"Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis","volume":"34","author":"Peters","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ejim.2011.06.006_bb0270","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/ard.2005.036269","article-title":"Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs","volume":"65","author":"Bolten","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0275","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2011.06.006_bb0280","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1001\/archinte.164.22.2472","article-title":"Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction","volume":"164","author":"Fischer","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2011.06.006_bb0285","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.berh.2006.03.003","article-title":"Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy","volume":"20","author":"Akkoc","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0290","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jbspin.2004.05.006","article-title":"Pleuropulmonary involvement in ankylosing spondylitis","volume":"72","author":"El Maghraoui","year":"2005","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ejim.2011.06.006_bb0295","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/ard.62.2.185","article-title":"Thoracic high resolution computed tomography in patients with ankylosing spondylitis and without respiratory symptoms","volume":"62","author":"El-Maghraoui","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2011.06.006_bb0300","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10067-003-0845-8","article-title":"Lung findings on thoracic high-resolution computed tomography in patients with ankylosing spondylitis. Correlations with disease duration, clinical findings and pulmonary function testing.","volume":"23","author":"El Maghraoui","year":"2004","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0305","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/bmj.329.7477.1266","article-title":"Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab","volume":"329","author":"Ostor","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2011.06.006_bb0310","first-page":"17","article-title":"El Maghraoui A","volume":"38","author":"Nouijai","year":"2009","journal-title":"Fibrosing alveolitis after treatement of rheumatoid arthritis by infliximab. Presse Med"},{"key":"10.1016\/j.ejim.2011.06.006_bb0315","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1183\/09031936.04.00076904","article-title":"Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis","volume":"24","author":"Bargagli","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2011.06.006_bb0320","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/rheumatology\/kei103","article-title":"British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments","volume":"44","author":"Ledingham","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ejim.2011.06.006_bb0325","first-page":"371","article-title":"Prevalence of subclinical amyloidosis in ankylosing spondylitis","volume":"34","author":"Singh","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0330","first-page":"912","article-title":"Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration","volume":"24","author":"Gratacos","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0335","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s10067-007-0679-x","article-title":"Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients","volume":"26","author":"Kobak","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2011.06.006_bb0340","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620511001166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620511001166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T09:27:41Z","timestamp":1543656461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620511001166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0953620511001166"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2011.06.006","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}